Skip to Content

Imunon Inc IMNN

Morningstar Rating
$1.16 −0.04 (3.68%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IMNN is trading at a 817% premium.
Price
$1.21
Fair Value
$6.94
Uncertainty
Extreme
1-Star Price
$13.23
5-Star Price
$7.17
Economic Moat
Mcbbd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMNN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.21
Day Range
$1.161.21
52-Week Range
$0.482.00
Bid/Ask
$1.16 / $1.17
Market Cap
$10.95 Mil
Volume/Avg
60,184 / 34,212

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body’s immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
33

Valuation

Metric
IMNN
Price/Earnings (Normalized)
Price/Book Value
1.34
Price/Sales
Price/Cash Flow
Price/Earnings
IMNN

Financial Strength

Metric
IMNN
Quick Ratio
2.04
Current Ratio
2.51
Interest Coverage
−555.91
Quick Ratio
IMNN

Profitability

Metric
IMNN
Return on Assets (Normalized)
−70.65%
Return on Equity (Normalized)
−105.61%
Return on Invested Capital (Normalized)
−93.55%
Return on Assets
IMNN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
QkyvrndspzZkpf$584.2 Bil
Vertex Pharmaceuticals Inc
VRTX
KqrwlmlnmWwsrpn$126.7 Bil
Regeneron Pharmaceuticals Inc
REGN
DkcghrbzqLpmlmp$116.9 Bil
Moderna Inc
MRNA
TmbrvqkqyYpjj$45.3 Bil
Alnylam Pharmaceuticals Inc
ALNY
ZwjwdxfgPmtyqd$29.9 Bil
argenx SE ADR
ARGX
FzkbpwjwcZdt$27.8 Bil
BioNTech SE ADR
BNTX
SdrznkcprLsmy$20.0 Bil
Biomarin Pharmaceutical Inc
BMRN
NqhqqgtJtzyqcs$16.1 Bil
United Therapeutics Corp
UTHR
VgrcsnvtVqwr$14.7 Bil
Incyte Corp
INCY
RyyqtpwlsBjbbpfv$13.2 Bil

Sponsor Center